Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.56 |
| ▸ | MAP2K2 | P36507 | 10/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29781375 | 1.00 | MAP2K1 (0.56) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29425357 | 1.00 | MAP2K1 (0.56) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL1341557 | 0.86 | MAP2K1 (0.55) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL23694151 | 0.86 | CSF1R (0.45) | MAP2K1MAP2K2BRAFMAPK1 | |
| SCHEMBL29781367 | 0.85 | MAP2K1 (0.74) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL5992602 | 0.85 | MAP2K1 (0.74) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL31401872 | 0.84 | MAP2K1 (0.53) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL23693785 | 0.84 | MAP2K1 (0.53) | MAP2K1MAP2K2PIM1CAMK2B | |
| SCHEMBL31401815 | 0.84 | MAP2K1 (0.53) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29425445 | 0.84 | MAP2K1 (0.53) | MAP2K1MAP2K2PIM1CAMK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117677607-A | Process for producing aryl amide derivative | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-31 | — | — | US | disclosed |
| EP-4186506-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-31 | — | — | EP | disclosed |
| CN-115803024-A | Composition comprising arylamide derivatives | 中外制药株式会社 | 2023-03-14 | — | — | CN | disclosed |
| WO-2023003014-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | 中外製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
| WO-2023003014-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | 中外製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-05 | — | — | US | disclosed |
| CN-114929669-A | Arylamide derivatives having antitumor activity | 中外制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021149776-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | 中外製薬株式会社 | 2021-07-29 | — | — | WO | disclosed |
| WO-2021149776-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | 中外製薬株式会社 | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | BRAF, NRAS, KRAS | MAP2K1 17/4885MAP2K2 11/4885PIM1 136/4885 |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | BRAF, NRAS, KRAS | MAP2K1 162/4885MAP2K2 132/4885PIM1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.